Corrigendum to “BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-induced migration, angiogenesis and permeability in tumor-derived endothelial cells”[Immunology Letters 230 (2021) 27–35]
Titel:
Corrigendum to “BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-induced migration, angiogenesis and permeability in tumor-derived endothelial cells”[Immunology Letters 230 (2021) 27–35]